 |
|
Preventive strategy for nonalcoholic fatty liver disease-related hepatocellular carcinoma
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(Suppl):S220-S227. Published online 2022 Nov 10 DOI: https://doi.org/10.3350/cmh.2022.0360
|
|
Citations to this article as recorded by
 Reassessing the Impact of Coffee Consumption on Liver Disease: Insights from a Large-Scale Cohort Study with IPTW Adjustment
Keungmo Yang, Young Chang, Soung Won Jeong, Jae Young Jang, Tom Ryu
Nutrients.2024; 16(13): 2020. CrossRef Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight
Anqi Li, Rui Wang, Yuqiang Zhao, Peiran Zhao, Jing Yang
Metabolites.2024; 14(6): 325. CrossRef Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
Alimentary Pharmacology & Therapeutics.2024;[Epub] CrossRef Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis
Zahid Ijaz Tarar, Umer Farooq, Faisal Inayat, Sanket D Basida, Faisal Ibrahim, Mustafa Gandhi, Gul Nawaz, Arslan Afzal, Ammad J Chaudhary, Faisal Kamal, Ahmad H Ali, Yezaz A Ghouri
World Journal of Experimental Medicine.2024;[Epub] CrossRef Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang
Clinical and Molecular Hepatology.2023; 29(2): 453. CrossRef Recent Insights into the Biomarkers, Molecular Targets and Mechanisms of Non-Alcoholic Steatohepatitis-Driven Hepatocarcinogenesis
Anna Kakehashi, Shugo Suzuki, Hideki Wanibuchi
Cancers.2023; 15(18): 4566. CrossRef
|